News

Zylet, which was approved for marketing by the FDA on December 15, is part of the loteprednol etabonate business that Pharmos sold to Bausch & Lomb in 2001.

Johnson & Johnson Pharmaceutical R&D (J&JPRD)announced that health authorities are reviewing scientific data from two clinical trials evaluating an investigational use of Reminyl (galantamine hydrobromide) in individuals with

In its decision, the US Court of Appeals for the Federal Circuit upheld an earlier ruling in Pfizer’s favor by the US District Court for the District of

Results from the eight-week study showed that Geodon (ziprasidone) and Risperdal (risperidone), advertised as the most frequently prescribed antipsychotic in the US, were equally effective in improving psychotic

The protocol was approved by the protocol review committee of the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP). Peregrine and the New Approaches to Brain Tumor

The research services business will be sold to a group led by the current management team of Pharma Medica. Consideration will consist of a cash payment of $14

The acquisition extends Pfizer’s research in the field of ophthalmology and will enable Angiosyn’s novel angiostatic agent to be further developed. The agent’s primary therapeutic indication is for

Financial terms of the deal, which is subject to normal closing conditions, have not been disclosed by the companies, but the acquisition is expected to close later in

This investigational new drug (IND) allowance moves Manhattan forward into the next stage of Oleoyl estrone (OE)’s development and was granted on the preclinical chemistry, manufacturing, and safety